Article ; Online: CIGB-258, a peptide derived from human heat-shock protein 60, decreases hyperinflammation in COVID-19 patients.
2021 Volume 26, Issue 3, Page(s) 515–525
Abstract: Hyperinflammation distinguishes COVID-19 patients who develop a slight disease or none, from those progressing to severe and critical conditions. CIGB-258 is a therapeutic option for the latter group of patients. This drug is an altered peptide ligand ( ... ...
| Abstract | Hyperinflammation distinguishes COVID-19 patients who develop a slight disease or none, from those progressing to severe and critical conditions. CIGB-258 is a therapeutic option for the latter group of patients. This drug is an altered peptide ligand (APL) derived from the cellular stress protein 60 (HSP60). In preclinical models, this peptide developed anti-inflammatory effects and increased regulatory T cell (Treg) activity. Results from a phase I clinical trial with rheumatoid arthritis (RA) patients indicated that CIGB-258 was safe and reduced inflammation. The aim of this study was to examine specific biomarkers associated with hyperinflammation, some cytokines linked to the cytokine storm granzyme B and perforin in a cohort of COVID-19 patients treated with this peptide. All critically ill patients were under invasive mechanical ventilation and received the intravenous administration of 1 or 2 mg of CIGB-258 every 12 h. Seriously ill patients were treated with oxygen therapy receiving 1 mg of CIGB-258 every 12 h and all patients recovered from their severe condition. Biomarker levels associated with hyperinflammation, such as interleukin (IL)-6, IL-10, tumor necrosis factor (TNF-α), granzyme B, and perforin, significantly decreased during treatment. Furthermore, we studied the ability of CIGB-258 to induce Tregs in COVID-19 patients and found that Tregs were induced in all patients studied. Altogether, these results support the therapeutic potential of CIGB-258 for diseases associated with hyperinflammation. Clinical trial registry: RPCEC00000313. |
|---|---|
| MeSH term(s) | Adult ; Aged ; Aged, 80 and over ; Anti-Inflammatory Agents/chemistry ; Anti-Inflammatory Agents/therapeutic use ; COVID-19/blood ; COVID-19/complications ; Chaperonin 60/chemistry ; Chaperonin 60/therapeutic use ; Cytokine Release Syndrome/blood ; Cytokine Release Syndrome/complications ; Cytokine Release Syndrome/drug therapy ; Female ; Humans ; Inflammation/blood ; Inflammation/complications ; Inflammation/drug therapy ; Interleukin-10/blood ; Interleukin-6/blood ; Male ; Middle Aged ; SARS-CoV-2/drug effects ; T-Lymphocytes, Regulatory/drug effects ; Tumor Necrosis Factor-alpha/blood ; Young Adult ; COVID-19 Drug Treatment |
| Chemical Substances | Anti-Inflammatory Agents ; Chaperonin 60 ; IL10 protein, human ; IL6 protein, human ; Interleukin-6 ; Tumor Necrosis Factor-alpha ; Interleukin-10 (130068-27-8) |
| Language | English |
| Publishing date | 2021-02-24 |
| Publishing country | Netherlands |
| Document type | Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't |
| ZDB-ID | 1362749-1 |
| ISSN | 1466-1268 ; 1355-8145 |
| ISSN (online) | 1466-1268 |
| ISSN | 1355-8145 |
| DOI | 10.1007/s12192-021-01197-2 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 4797: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.